SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys is focused on leveraging its unique proprietary platform to manufacture high-value proteins and oils. SemBioSys’ seed-based protein production system can provide for its partners product enablement, exceptionally low cost and unprecedented scalability. SemBioSys is applying the platform with high selectivity to products with tremendous clinical promise and value potential. The Company’s current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI Milano, a next-generation cardiovascular therapy. SemBioSys' proprietary safflower-derived Apo AIMilano is a des-1,2- variant of Apo AI Milano as previously described in the literature. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS.